Global Intravenous Iron Drugs Market 2017-2021

This market research study identifies Allergan, AMAG Pharmaceuticals, Daiichi Sankyo, Galenica, and Pharmacosmos as the leading players in the global intravenous (IV) iron drugs market. A comprehensive analysis of this market is also presented by the product type (ferric carboxy maltose, sucrose, dextran, and others) and by geography (the Americas, APAC, and EMEA).

Overview of the global intravenous iron drugs market

According to Technavio’s market research analysts, the global intravenous iron drugs market will grow at a steady rate and post a CAGR of more than 10% during the forecast period. The growing demand for non-dextran IV iron drugs will drive the growth prospects for the global intravenous iron drugs market until the end of 2021. The market is witnessing a high degree of shift from conventional dextran intravenous iron drugs to non-dextran intravenous iron drugs due to the growing demand for non-dextran intravenous iron drugs, which in turn, will fuel the market’s growth in the coming years. One of the major factors responsible for the growing demand for non-dextran intravenous iron drugs is its ability to deliver larger doses of iron infusion in a short time. Furthermore, these drugs also have the ability to address challenges such as intolerance or an unsatisfactory response, safety concerns, and dosing and compliance issues associated with conventional iron therapies, which will again, fuel their demand in the coming years.

The increase in favorable guidelines from health care organizations will drive the growth prospects for the global intravenous iron drugs market for the next four years. For instance, the European Society of Cardiology posted guidelines that strongly recommend the use of Ferinject for the treatment of iron deficiency in patients with systolic heart failure, in turn, driving the adoption rate of intravenous iron drugs.

Competitive landscape and key vendors

The global intravenous iron drugs market is highly competitive and diversified due to the presence of a large number of regional and international vendors across the globe. It has been observed that these vendors are increasingly competing against each other based on factors such as aggressive pricing, novel therapeutics, and technological advancements. The development of non-dextran therapies, expansion of applications, awareness programs, cost-effective drugs, and effective marketing strategies are some of the strategic success factors of the major players in the market. Furthermore, these vendors are also increasingly focusing on the development of novel drugs such as ferric carboxy maltose.

Key vendors in this market are -

• Allergan
• AMAG Pharmaceuticals
• Daiichi Sankyo
• Galenica
• Pharmacosmos

Other prominent vendors in the market include Nippon Shinyaku, NOXXON Pharma, Rockwell Medical, Sanofi, and Wanbang Biopharmaceutical.

Segmentation by product type and analysis of the intravenous iron drugs market

• Ferric carboxy maltose
• Sucrose
• Dextran

The ferric carboxy maltose segment accounted for the majority market share during 2016 and will continue to dominate the market for the next four years. Some of the major factors responsible for the market segment's growth is the increasing number of benefits of ferric carboxy maltose over other conventional drugs, their safety and efficacy profiles, and the ability to rapidly replace iron stores in the body. Moreover, these drugs can also be prescribed in higher doses in comparison to conventional drugs. For instance, the dosage range of ferric carboxy maltose is 500-1000 mg/infusion.

Segmentation by geography and analysis of the intravenous iron drugs market

• Americas
• APAC
• EMEA

In terms of geography, the Americas accounted for the majority market share during 2016 and will continue to dominate the market during the forecasted period. One of the major factors responsible for the market's growth in the region is the expansion strategies adopted by a large number of vendors that will boost the consumption and product reach across the Americas. Furthermore, the increasing incidence of iron deficiency anemia will further fuel the consumption of intravenous iron drugs, which, in turn, will propel the rate of revenue generation in the market.

Key questions answered in the report include

• What will the market size and the growth rate be in 2021?
• What are the key factors driving the global intravenous iron drugs market?
• What are the key market trends impacting the growth of the global intravenous iron drugs market?
• What are the challenges to market growth?
• Who are the key vendors in the global intravenous iron drugs market?
• What are the market opportunities and threats faced by the vendors in the global intravenous iron drugs market?
• What are the trending factors influencing the market shares of the Americas, APAC, and EMEA?
• What are the key outcomes of the five forces analysis of the global intravenous iron drugs market?

Technavio also offers customization on reports based on specific client requirement.